Seladelpar conditionally approved in European Union to help treat PBC
Gilead Sciences’ oral therapy seladelpar has been conditionally approved by the European Commission as a second-line therapy for adults with primary biliary…
News
Combo of variants in ABCB4 gene could lead to ICP, study finds
A specific variant in the ABCB4 gene does not cause intrahepatic cholestasis of pregnancy (ICP) on its own, but it may increase the disease’s…
Algorithm spots people with MASLD, MASH using health records
Researchers have developed an algorithm to identify people with metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver disease, based on information…
Patient identification guidelines may help diagnose biliary atresia earlier
A team of experts in the U.S. and Canada have developed patient identification guidelines to help pediatric primary care providers, or PCPs, in making an…
Hepatitis B gene-editing therapy PBGENE-HBV shows early promise
A single dose of Precision BioSciences’ investigational gene-editing therapy PBGENE-HBV was well tolerated and showed early signs of antiviral activity among three adults with…
2nd liver transplant linked to good outcomes in PSC
A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…
AI models may aid intrahepatic cholestasis of pregnancy prediction
New artificial intelligence (AI) models based on 11 possible risk factors of intrahepatic cholestasis of pregnancy (ICP) can accurately distinguish between healthy pregnant women,…
Phase 2 trial of DD01 in treating MASH completes enrollment
D&D Pharmatech has finished enrolling a Phase 2 clinical trial of its experimental therapy DD01 in overweight or obese adults with metabolic dysfunction-associated steatohepatitis…
Poor access to genetic testing may delay Alagille syndrome diagnosis
Difficulty accessing genetic testing in low- to middle-income countries may delay the diagnosis of Alagille syndrome in children and lead to misdiagnoses that may…
Dosing complete in Phase 2b trial of AHB-137 for hepatitis B
A Phase 2b clinical trial testing AusperBio’s investigational therapy AHB-137 in people with chronic hepatitis B has completed dosing and is now unblinded,…
